This document presents
the Perinatal Institute’s response to the
fetal growth section (Chapter
12) of the new NICE
antenatal guideline
and seeks to address the confusion which
has been generated by these new guidelines.
The NICE
recommendations
Two prominent recommendations
in the 2007
consultation guideline[2] have since been droppedfollowing evidence from stakeholders,
including the Perinatal Institute's submission
[3]. These were that
a fundal height +/ 3cm
from gestational age should be the trigger
for further investigation, and
customised charts should
not be used
The recommendations in the revised Guidelines
are now that
Symphysis-fundal height should be measured
and recorded at each antenatal appointment
from 24 weeks.
Ultrasound estimation of fetal size
for suspected large-for-gestational-age
unborn babies should not be undertaken
in a low-risk population.
Routine Doppler ultrasound in low-risk
pregnancies should not be used
We consider these
recommendations to be incomplete,
as there is no guidance as to how to undertake
or interpret fundal height measurements,
what constitutes normal growth and what
triggers cause for concern needing referral.
Recommendations
by the Perinatal Institute and the RCOG
The Perinatal Institute
has established recommendations for best
practice which are consistent with the 2002
RCOG Green Top Guidelines[4]. These have been written
by an independent group of experts and have
fully endorsed customised charts. Based
on this recommendation, the Perinatal Institute
has established an implementation programme.
To date, staff from over 90 NHS maternity
units in all NHS regions have been trained,
and are using this method for fetal surveillance
for about 200,000 expectant mothers each
year. We recommend that:
Fundal height should be measured at
each antenatal visit from 26 weeks gestation
The measurement should be plotted on
customised growth charts adjusted for
maternal height, weight in early pregnancy,
parity and ethnic origin.
A fetal growth scan should be offered
if the first fundal height measurement
is below the 10th centile on the customised
chart or serial measurements have shown
a slowing of growth.
The results of the ultrasound biometry,
expressed as estimated fetal weight (EFW),
should be plotted on the customised growth
chart to assess relative size-for gestation,
(or growth if a previous EFW has been
plotted)
An EFW below the 10th centile on the
customised chart, or slow EFW growth,
is an indication for assessment of umbilical
artery Doppler flow.
Clear guidance on fetal growth assessment
is important because of the strong links
between growth restriction and adverse
perinatal outcome, and we know from systematic
reviews that appropriate investigation
of SGA babies reduces perinatal deaths
[5].
By conventional methods,
only about a third of SGA babies are detected
antenatally. In a controlled study[6], measuring and plotting
of fundal height on customised charts has
been shown to significantly increase SGA
detection while reducing unnecessary referrals
for investigation. These results have since
been confirmed by another study
[7]. A recently completed confidential
enquiry into stillbirths with fetal
growth restriction has found that several
deaths could have been potentially avoided
if customised instead of population charts
had been used
[8].
Research
The NICE guidelines include
a research recommendation to evaluate effectiveness.
However the feasibility of proving such
effectiveness in prospective studies, e.g.
RCTs, is doubtful. Effectiveness is usually
measured by ‘hard’ pregnancy outcome such
as stillbirth. Analysis of a large database
of stillbirths
[9] showed that approximately 40% are associated
with fetal growth restriction and about
half occur at mature gestations allowing
early delivery without increasing neonatal
morbidity. A reduction of such deaths by
half would require about 250,000
consenting mothers in each arm
of the study. A more realistic (but still
optimistic) reduction of IUGR related deaths
by a third would require 560,000
mothers in each arm. In addition, such a
study would have to assume that standard
management protocols and practices are in
place across the NHS once a growth problem
is suspected - which is not the case. Some
of these issues are well illustrated by
the example of the 6-year multi-centre Growth
Restriction Intervention Trial [10].
The Perinatal Institute believes that
evidence for customised charts is already
conclusive without an RCT, while there
is little evidence to support the continued
use of population charts for assessing
fetal growth and weight. We will continue
to implement and support customised charts
for surveillance of fetal growth in all
units which wish to use them. We have
also established data collection to evaluate
the effect of customised charts in practice,
and will be pleased to support any unit
who wishes to audit their own use of customised
charts.
Concerns about quality
and process
Quality issues were apparent
as soon as the new guidelines were published
for consultation. As a number of changes
were required, we requested an additional
round of consultation. This was denied,
even though there is provision for this
under Chapter 14 of the NICE
Guidelines Manual
[11] in cases of mis-interpreted evidence
or omitted information, both of which circumstances
were present. A number of flaws thus remain
in the published final guideline.
The main concerns can be
summarised as follows:
The
GDG included no members with in-depth
knowledge of fetal growth screening
on its panel.
No
experts were invited, even though other
GDGs often invite special advisors to
assist with deliberations.
The
guideline misquotes customised charts
in the introduction (p
272),
stating that they ‘take into consideration
maternal characteristics such as height,
country of family origin, cigarette
smoking and diabetes’. In fact, as clearly
described in the literature, customised
charts present an ‘optimal’ standard
which excludes pathological
factors such as smoking and diabetes,
and adjusts for constitutional variables
such as maternal height booking weight,
parity and ethnic origin.
A
criterion was applied whereby the customised
charts had to demonstrate their prospective
effectiveness, while the same is not
expected of methods using population
charts.
The
GDG reviewed some but not other retrospective
analyses. For example, a report
from New Zealand
[12] found that SGA determined by customised
centiles were much more strongly associated
with perinatal mortality, abnormal umbilical
artery Doppler, caesarean section for
fetal distress, low Apgar score, admission
to the neonatal unit, high neonatal
morbidity index, and prolonged stay.
The
GDG failed to include a report
from an NHS maternity unit with
a multi-ethnic population which showed
that use of customised charts in the
NHS reduces unnecessary inductions
and other interventions
[13].
The
GDG did not include, in section 12.2.6,
evidence from a controlled
study
[6] which showed that FH measurement
by customised charts significantly improve
the detection of SGA, while reducing
unnecessary investigations.
The GDG advocate
fundal height measurement in their recommendation,
while no mention is made how this should
be performed, what represents normal,
and what would constitute a trigger
for further investigation.
The Perinatal Institute
has written to NICE to highlight the concerns
about the quality of the work which was
carried out by this Guideline Development
Group on behalf of the National Collaborating
Centre. It has called for rigorous quality
assurance in guideline development, the
involvement of experts, and more than a
single round of consultation to ensure that
GDGs have sufficient support with the assessment
and incorporation of evidence.
We welcome your comments - please send
them to grow@pi.nhs.uk
References
[1]
NICE, Antenatal care routine care
for the healthy pregnant woman, Clinical
Guideline,
NICE March 2008
[2]
NICE, Antenatal care routine care
for the healthy pregnant woman, Draft
for consultation,
NICE October 2007
[3]
Perinatal Institute, Stakeholder
response – Antenatal Care (partial
Update) Guideline, 2007: www.pi.nhs.uk/nice/PI_Stakeholder_Response.pdf,
[4]
Royal College of Obstetricians
and Gynaecologists. The investigation
and management of the small-for-gestational
age fetus. RCOG Green Top Guideline
2002(No.31),
[5]
Alfirevic Z, Nielson JP. Doppler
ultrasonography in high risk pregnancies:
systematic review with meta-analysis.
Am J Obstet Gynecol 1995;172:1379-87. Abstract
[6]
Gardosi J & Francis A. Controlled
trial of fundal height measurement
plotted on customised antenatal growth
charts. Br J Obstet Gynaecol 1999;106:39-17,
[7]
Wright J, Morse K, Kady S et al.
Audit of fundal height measurement
plotted on customised growth charts.
MIDIRS Midwifery Digest 2006; 16:341-45,
[8]
Perinatal Institute. Confidential
Enquiry into Stillbirths with Fetal
Growth Restriction 2007
www.pi.nhs.uk/rpnm/CE_SB_Final.pdf,
[9]
Gardosi J, Sue M Kady, Pat
McGeown, Andre Francis, Ann Tonks.
Classification of stillbirth by relevant
condition at death (ReCoDe): population
based cohort study. Br Med J 2005;331:1113-1117,
[10]
GRIT Study Group, A randomised
trial of timed delivery for the compromised
preterm fetus: short term outcomes
and Bayesian interpretation. BJOG.
2003 110(1):27-32. Abstract
McCowan L, Harding JE, Stewart
AW. Customised birthweight centiles
predict SGA pregnancies with perinatal
morbidity. Br J Obstet Gynaecol 2005;112:1026-1033
[13]
Dua & Schram C. An investigation
into the applicability of customised
charts for the assessment of fetal
growth in antenatal population at
Blackburn, Lancashire, UK. J Obstet
Gynaecol 2006; 26(5): 411-413